Trial Profile
A Randomized, Double-Blinded, Placebo-Controlled Phase 1/2 Dose-Range-Finding Study to Evaluate the Safety, Efficacy and PK of Multiple Once Daily Intravenous Doses of TSC in Patients With Intermittent Claudication
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 30 Jan 2018
Price :
$35
*
At a glance
- Drugs Transcrocetinate sodium (Primary)
- Indications Intermittent claudication
- Focus Adverse reactions
- Sponsors Diffusion Pharmaceuticals
- 08 Dec 2014 New trial record